Vanda Pharmaceuticals Inc. (VNDA): R&D Expense
$109.27M
Year ended 2025-12-31
$116.96M
Trailing 12 months to 2026-06-30
+8.4%
3-year compound annual growth
+14.5%
5-year compound annual growth
+14.1%
10-year compound annual growth
| Period ended | R&D Expense | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | $109.27M | +46.8% | 2026-02-12, From 2025-01-01 |
| 2024-12-31 | $74.43M | -3.1% | 2026-02-12, From 2024-01-01 |
| 2023-12-31 | $76.82M | -10.4% | 2026-02-12, From 2023-01-01 |
| 2022-12-31 | $85.77M | +13.8% | 2025-02-14, From 2022-01-01 |
| 2021-12-31 | $75.36M | +35.6% | 2024-02-08, From 2021-01-01 |
| 2020-12-31 | $55.58M | +14.2% | 2023-02-09, From 2020-01-01 |
| 2019-12-31 | $48.65M | +11.6% | 2022-02-24, From 2019-01-01 |
| 2018-12-31 | $43.59M | +13.1% | 2021-02-11, From 2018-01-01 |
| 2017-12-31 | $38.55M | +32.2% | 2020-02-26, From 2017-01-01 |
| 2016-12-31 | $29.16M | 0.0% | 2019-02-19, From 2016-01-01 |
| 2015-12-31 | $29.14M | +51.6% | 2018-02-15, From 2015-01-01 |
| 2014-12-31 | $19.23M | -32.5% | 2017-02-17, From 2014-01-01 |
| 2013-12-31 | $28.50M | -37.7% | 2016-02-12, From 2013-01-01 |
| 2012-12-31 | $45.76M | +57.8% | 2015-03-13, From 2012-01-01 |
| 2011-12-31 | $29.00M | +135.0% | 2014-02-25, From 2011-01-01 |
| 2010-12-31 | $12.34M | -11.1% | 2013-02-26, From 2010-01-01 |
| 2009-12-31 | $13.87M | n/a | 2012-03-09, From 2009-01-01 |
R&D Expense at similar companies
| Company | Year ended | R&D Expense | Change YoY |
|---|---|---|---|
| Vanda Pharmaceuticals Inc. (VNDA) | 2025-12-31 | $109.27M | +46.8% |
| Amarin Corp PLC (AMRN) | 2025-12-31 | $19.81M | -5.1% |
| IDEAYA Biosciences, Inc. (IDYA) | 2025-12-31 | $314.70M | +6.8% |
| Puma Biotechnology, Inc. (PBYI) | 2025-12-31 | $62.07M | +13.0% |
| Anaptysbio, Inc (ANAB) | 2025-12-31 | $135.97M | -17.0% |
| Akebia Therapeutics, Inc. (AKBA) | 2025-12-31 | $62.36M | +65.6% |
| Keros Therapeutics, Inc. (KROS) | 2025-12-31 | $129.64M | -25.3% |
| Rhythm Pharmaceuticals, Inc. (RYTM) | 2025-12-31 | $167.34M | -29.7% |
| Arcus Biosciences, Inc. (RCUS) | 2025-12-31 | $523.00M | +16.7% |
Compare VNDA, AMRN, IDYA, PBYI side by side · Screen every company in Pharmaceutical Preparations ↗